Free Trial

Richard Vosser Analyst Performance

Analyst at JPMorgan Chase & Co.

Richard Vosser is a stock analyst at JPMorgan Chase & Co. in the healthcare sector, covering 8 publicly traded companies. Over the past year, Richard Vosser has issued 5 stock ratings, including buy and hold recommendations. While full access to Richard Vosser's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Richard Vosser's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
23 Last 9 Years
Buy Recommendations
17.39% 4 Buy Ratings
Companies Covered
8 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy17.4%4 ratings
Hold78.3%18 ratings
Sell4.3%1 ratings

Out of 23 total stock ratings issued by Richard Vosser at JPMorgan Chase & Co., the majority (78.3%) have been Hold recommendations, followed by 17.4% Buy and 4.3% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
37.5% of companies on NASDAQ
3 companies
OTCMKTS
37.5% of companies on OTCMKTS
3 companies
NYSE
25.0% of companies on NYSE
2 companies

Richard Vosser, an analyst at JPMorgan Chase & Co., currently covers 8 companies listed on NASDAQ, OTCMKTS and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
8 companies
100.0%

Richard Vosser of JPMorgan Chase & Co. specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
PHARMACEUTICALS
6 companies
75.0%
BIOTECHNOLOGY
2 companies
25.0%

Richard Vosser's Ratings History at JPMorgan Chase & Co.

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Grifols, S.A. stock logo
GRFS
Grifols
10/26/2026Lower Price Target$8.01$9.00Neutral
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2/24/2026Downgrade$39.68Neutral
Sanofi stock logo
SNY
Sanofi
12/8/2025Reiterated Rating$49.53Neutral
Novartis AG stock logo
NVS
Novartis
12/8/2025Upgrade$132.42Overweight
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
12/8/2025Lower Price Target$4.20$3.75Neutral
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
9/3/2025Lower Price Target$3.73$4.00Neutral
Sanofi stock logo
SNY
Sanofi
8/8/2025Upgrade$47.43Overweight